BioSpace News Archive

Gryphon Investors (“Gryphon”), a leading middle-market private equity firm, today announced that it has acquired Vetnique Labs (“Vetnique” or the “Company”).

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, May 3rd at 11:30 a.m. Eastern Time to discuss its first quarter 2023 financial results.

Luxa Biotechnology today announced the company will provide an update on the progress of a Phase 1/2a clinical trial evaluating transplantation of RPESC-RPE-4W to treat dry age-related macular degeneration (AMD) at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held in New Orleans from April 23– 27, 2023.

Castle Biosciences, Inc. today announced new data from a patient simulation study which showed that, compared to pathology alone, TissueCypher® Barrett’s Esophagus test results may significantly increase the likelihood of appropriate management decisions for Barrett’s esophagus (BE) patients with low-grade dysplasia (LGD) according to their risk of progressing to esophageal cancer.

Bausch + Lomb Corporation today announced the presentation of eight scientific poster presentations during the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which will take place in New Orleans from April 23-27, 2023.

Abata Therapeutics today announced the appointment of Leonard “Lenny” Dragone, M.D., Ph.D., as its new chief medical officer.

Anaconda Biomed today announced the appointment of a new board chairperson, and the naming of a new chief medical officer.

BeiGene today announced the global RATIONALE 305 trial met its primary endpoint of overall survival, with tislelizumab in combination with chemotherapy demonstrating superior overall survival (OS) compared with chemotherapy in patients with advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, regardless of PD-L1 status.

Promore Pharma (STO:PROMO) (FRA:8T0) The Board of Directors of Emplicure AB has decided to change the date of the company’s Annual General Meeting to June 27, 2023.

TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD ™ Method in Stage IV Uveal Melanoma Patients With Liver Metastases.